Primary Record
Baricitinib
- In stock
- 2,256 g
- Purity
- 98.6 %
- CAS
- 1187594-09-7
Compound Identifiers & Properties
- CAS
- 1187594-09-7
- PubChem CID
- 44205240
- SMILES
- CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
- Canonical SMILES
- CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Names & Synonyms
- Baricitinib
- olumiant
- 1187594-09-7
- baricitinibum
- INCB028050
- Baricitinib phosphate
- Baricitinib [USAN]
- Olumiant (TN)
- INCB 028050
- LY3009104
- Baricitinib (phosphate)
- Baricitinib [USAN:INN]
- INCB-028050
- Baricitinib (Standard)
- RefChem:6387
- UNII-ISP4442I3Y
- ISP4442I3Y
- BARICITINIB [MI]
- BARICITINIB [INN]
- BARICITINIB [JAN]
- Baricitinib phosphate salt
- C16H17N7O2S
- D0Y7IC
- JAK inhibitors: baricitinib
- MFCD21608464
- BARICITINIB [WHO-DD]
- cc-652
- CHEBI:95341
- MLS006011247
- SCHEMBL871150
- DTXSID30152228
- LY 3009104
- LY-3009104
- Baricitinib (JAN/USAN/INN)
- Baricitinib (LY3009104)
- BARICITINIB [EMA EPAR]
- Baricitinib (INCB028050)
- GTPL7792
- INCB 28050
- INCB-28050
- orb1305415
- Baricitinib - Bio-X trade mark
- CHEMBL2105759
- DTXCID5074719
- SCHEMBL27246146
- SCHEMBL28628968
- SCHEMBL29349824
- AMMD00005
- INCB28050
- BARICITINIB [ORANGE BOOK]
- EX-A413
- L04AA37
- QCR-197
- XUZMWHLSFXCVMG-UHFFFAOYSA-N
- GLXC-90043
- HMS3651L17
- HMS3672M15
- HMS3747G21
- HMS5081F19
- AOB87724
- BCP04686
- 1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile
- 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile
- Baricitinib (LY3009104, INCB028050)
- ABP001023
- BDBM50021656
- EBC-11468
- HY-15315R
- NSC799357
- s2851
- ZINC73069247
- AKOS022186127
- AKOS025401933
- AM81232
- BCP9000380
- CCG-268312
- CS-0724
- DB11817
- DS-7641
- FE30357
- NSC-799357
- PB27275
- RL00725
- SB10845
- SDCCGSBI-0654448.P001
- KS-0000044L
- NCGC00345839-01
- NCGC00345839-14
- NCGC00345839-16
- AC-27404
- AK143352
- BB184033
- BC600315
- DA-50940
- HY-15315
- SC-94301
- SMR004703006
- BCP0726000031
- AB0035958
- AJ-121247
- A3222
- A4141
- FT-0775037
- NS00072974
- SW220096-1
- Y0439
- 2-(3-(4-(3H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile
- Baricitinib (INCB28050, LY3009104)?
- J3.196.953K
- A11329
- D10308
- LY3009104 (phosphate);INCB028050 (phosphate)
- S-7686
- 2-[1-ETHYLSULFONYL-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PYRAZOL-1-YL]AZETIDIN-3-YL]ACETONITRILE
- A892931
- EN300-24435973
- F468368
- 1187595-84-1
- Q4860707
- BRD-K53581288-001-02-9
- 3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-
- Z2724205326
- B0084-457382
- 2-[1-(ethanesulfonyl)-3-(4-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}-1H-pyrazol-1-yl)azetidin-3-yl]acetonitrile
- (1-(Ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile
- (1-(Ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)ethanenitrile
- {1-(Ethanesulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile
- {1-(ethylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azetidin-3-yl}acetonitrile
- 1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidine-4-yl)-1H-pyrazol-1-yl]-3-(cyanomethyl)azetidine
- 2-(3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile
- 3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-; 1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile; Baricitinib; INCB 028050; INCB 28050; LY 3009104; Olumiant
- 3-Azetidineacetonitrile,1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-
- 3JW
- Ethyl[3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-(cyanomethyl)azetidin-1-yl] sulfone
- INCB-028050|||LY-3009104|||2-[1-Ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile